BARICITINIB: NEW PHARMACOTHERAPY OPTIONS FOR RHEUMATOID ARTHRITIS AND OTHER IMMUNE-MEDIATED INFLAMMATORY RHEUMATIC DISEASES-Reference-Cited by-同舟云学术

BARICITINIB: NEW PHARMACOTHERAPY OPTIONS FOR RHEUMATOID ARTHRITIS AND OTHER IMMUNE-MEDIATED INFLAMMATORY RHEUMATIC DISEASES

Published:2020-06-24 Issue:3 Volume:58 Page:304-316
ISSN:1995-4492
Container-title:Rheumatology Science and Practice
language:
Short-container-title:Naučno-praktičeskaâ revmatologiâ

Author:

Nasonov E. L.¹^ORCID,Lila A. M.²^ORCID

Affiliation:

1. V.A. Nasonova Research Institute of Rheumatology; I.M. Sechenov First Moscow State Medical University (Sechenov University), Ministry of Health of Russia

2. V.A. Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuing Professional Education, Ministry of Health of Russia

Abstract

Deciphering the mechanisms of the pathogenesis of immune-mediated inflammatory rheumatic diseases (IMIRDs) in conjunction with designing a wide range of biological agents is one of the major medical advances in the 21st century. A new promising area of pharmacotherapy for IMIRDs is associated with the design of the so-called targeted oral medications that primarily include Janus kinase (JAK) inhibitors. The review presents new data on the efficacy and safety of the new JAK inhibitor baricitinib in treating rheumatoid arthritis and other IMIRDs.

Publisher

Mediar Press

Subject

Immunology,Immunology and Allergy,Rheumatology

Reference131 articles.

1. Baker KF, Isaacs JD. Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis? Ann Rheum Dis. 2018;77(2):175-87. doi: 10.1136/annrheumdis-2017-211555

2. Nasonov EL. Farmakoterapiya revmatoidnogo artrita: novaya strategiya, novye misheni. Nauchno-prakticheskaya revmatologiya. 2017;55(4):409-19. doi: 10.14412/1995-4484-2017-409-19 [Nasonov EL. Pharmacotherapy for rheumatoid arthritis: New strategy, new targets. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2017;55(4):409-19. doi: 10.14412/1995-4484-2017-409-419 (In Russ.)].

3. Burmester GR, Bijlsma JWJ, Cutolo M, McInnes IB. Managing rheumatic and musculoskeletal diseases – past, present and future. Nat Rev Rheumatol. 2017;13(7):443-8. doi: 10.1038/nrrheum.2017.95

4. Schwartz DM, Kanno Y, Villarino A, et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017;16(12):843-62. doi: 10.1038/rd.2017.201

5. Nasonov EL, Lila AM. Ingibitory Yanus-kinaz pri immunovospalitel'nykh revmaticheskikh zabolevaniyakh: novye vozmozhnosti i perspektivy. Nauchno-prakticheskaya revmatologiya. 2019;57(1):8-16. doi: 10.14412/1995-4484-2019-8-16 [Nasonov EL, Lila AM. Janus kinase inhibitors in immunoinflammatory rheumatic diseases: new opportunities and prospects. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2019;57(1):8-16. doi: 10.14412/1995-4484-2019-8-16 (In Russ.)].

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The use of methotrexate in rheumatoid arthritis. Recommendations of the All-Russian public organization “Association of Rheumatologists of Russia”;Rheumatology Science and Practice;2023-08-31

2. Rheumatoid arthritis as a clinical and immunological syndrome: focus on the seronegative subtype of the disease;Rheumatology Science and Practice;2023-06-28

3. Updated American College of Rheumatology/American Association of Hip and Knee Surgeons guideline for the perioperative management of antirheumatic medication in patients with rheumatic diseases undergoing elective total hip or total knee arthroplasty 2022;Rheumatology Science and Practice;2023-06-28

4. Janus kinase inhibitors in immunoinflammatory rheumatic diseases;Terapevticheskii arkhiv;2022-06-17

5. Janus kinase inhibitors in immunoinflammatory diseases: 10 years of clinical practice in rheumatology;Rheumatology Science and Practice;2022-05-13